HHS

The purpose of this Funding Opportunity Announcement (FOA) is to solicit research applications for milestone-driven projects focused on preclinical development of lead candidate therapeutics, vaccines and related countermeasures against select NIAID Emerging Infectious Diseases/Pathogens. Applications must include a Product Development Strategy attachment and demonstrate substantive investment by at least one industrial participant.

The purpose of this Funding Opportunity Announcement (FOA) is to support the use of Collaborative Cross (CC) mouse lines to advance understanding of the host genetics involved in immune regulation and function and to further develop CC mouse lines that more faithfully reproduce human immune responses. Applicants may include CC, CC derivatives with reproducible genomes and/or CC-RIX mice to accomplish these goals. Research areas supported by this FOA include immune system development, function or regulation; mechanisms governing immune response to infectious pathogens, vaccines or adjuvants; host susceptibility factors and mechanisms of pathogen-induced immunopathology; and immune mechanisms involved in the development and progression of immune-mediated diseases, such as allergy/asthma, autoimmunity, primary immunodeficiency, inflammation, and cell/organ/tissue transplant rejection or tolerance.

The latest BARDA Broad Agency Announcement (BAA) is amendment 14 posted on March 9, 2020.

Note: COVID-19 response related Areas of Interest includes:

AOI 7.7.1 Diagnostic assay for human coronavirus using existing FDA-cleared platforms
AOI 7.7.2 Point-of-care diagnostic assay for detection of SARS-CoV-2 virus
AOI 7.7.3 Diagnostic assay for detection of COVID-19 disease (SARS-CoV-2 infection)
AOI 8.3 COVID-19 Vaccine
AOI 9.2 COVID-19 Therapeutics
AOI 9.3 Immunomodulators or therapeutics targeting lung repair
AOI 9.5 Pre-exposure and post-exposure prophylaxis
AOI 10 Respiratory protective devices
AOI 11 Ventilators
AOI 17 Advanced Manufacturing Technologies

NHLBI is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Coronavirus Disease 2019 (COVID-19) and on biological effects of its causative agent, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Topics of specific interest to NHLBI include host response, associations with heart, lung, and blood (HLB) diseases, potential impacts on transfusion safety, and clinical outcomes of infected individuals.

Participating ICs at the time of publication: NCI, NCCIH, NHGRI, NIAID, NICHD, NIDDK, NIEHS, NIGMS, NIMHD, NIBIB. Emergency Notices of Special Interest (NOSIs) issued by the respective ICs will specify the activity codes under which recipients can apply. The National Institutes of Health (NIH) hereby notify the applicant community that funds may be available for applications based on a presidentially declared disaster under the Stafford Act, a public health emergency declared by the Secretary, HHS, or other local, regional or national disaster.

Applications for Emergency Competitive Revisions will be routed directly to the NIH awarding component listed on the NoA of the most recent parent award.

Only applications submitted in response to an Emergency Notice of Special Interest (NOSI) published by an IC will be allowed to apply to this FOA.

NIGMS will accept the submission of applications for Competitive Revisions to active grants to address only the following research areas of interest:

Incorporation of data related to SARS-CoV-2 into ongoing research efforts to develop predictive models for the spread of SARS-CoV-2 and other related infectious agents (all relevant grants).

Repurposing or modification of diagnostic tools currently under development to enable rapid detection of SARS-CoV-2 infection (SBIR/STTR grants only).

Rapid development of potential therapeutic agents for COVID-19 (SBIR/STTR only).

The purpose of this supplement is to provide support for the conduct of worker-based training to prevent and reduce exposure of hospital employees, emergency first responders, and other workers who are at risk of exposure to Coronavirus through their work duties. The NIEHS Superfund Worker Training Program (WTP) will work collaboratively to develop and target safety and health training for those workers supporting the national Coronavirus response. Using our hazmat trainers’ understanding of worker safety and health protection issues, knowledge of personal protective equipment (PPE) usage, and experience in training disaster workers, WTP will coordinate with the Centers for Disease Control and Prevention (CDC), the Occupational Safety and Health Administration (OSHA), and the National Institute for Occupational Safety and Health (NIOSH) to provide awardees with material to develop an evidence-based curriculum that addresses the science of Coronavirus (clinical symptoms, mode of transmission, persistence in the environment, and treatment); infection control and worker protection (isolation/quarantine and PPE); working in the contaminated environment (sampling and decontamination); and behavioral health resiliency . The funding for this supplement is provided from the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020.

NIAID is issuing this Notice of Special Interest (NOSI) to highlight the need for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). NIAID is particularly interested in projects focusing on viral natural history, pathogenicity, transmission, as well as projects developing medical countermeasures and suitable animal models for pre-clinical testing of vaccines and therapeutics against SARS-CoV-2/COVID-19.

The purpose of this Notice is to inform applicants that the National Institute of Biomedical Imaging and Bioengineering (NIBIB) will participate, effective immediately, in PA-20-135 "Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)".

The following changes and updates are made to PA-20-135 (shown in italics) to reflect NIBIB participation in this FOA.

AHRQ intends to publish a new funding notice allowing requests for urgent revision supplements to existing AHRQ grants and cooperative agreements to address health system responsiveness to COVID-19. AHRQ intends to allow grantees with active AHRQ research grants to submit requests for competitive revision supplements to address timely health system and healthcare professional response to COVID-19. Grant activity codes to be included or excluded from the funding notice will specified in the announcement.

It is expected that competitive revision supplement requests will capitalize on the expertise of grant personnel and the institutional environment to expand the specific aims of the on-going research to develop high-impact new knowledge concerning COVID-19. Competitive revision supplements will be limited in duration (perhaps 12 months). The amount of supplemental funds that may be requested will be limited, and will be specified in the funding notice. AHRQ expects to make at least $2.5M available to fund meritorious revision supplements in FY2020. AHRQ plans to release the supplement announcement in April 2020 with an opening date in mid-May.